QuiaPEG Pharmaceuticals Holding AB (publ) (QUIA.ST)
SEK 0.01
(10.28%)
SEK 0.01
(10.28%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 41.95 Million SEK | 78.99% |
| 2022 | 23.44 Million SEK | -1.35% |
| 2021 | 23.76 Million SEK | 15.68% |
| 2020 | 20.54 Million SEK | 35.07% |
| 2019 | 15.2 Million SEK | 63.05% |
| 2018 | 9.32 Million SEK | -26.7% |
| 2017 | 12.72 Million SEK | -42.4% |
| 2016 | 22.09 Million SEK | 148.76% |
| 2015 | 8.88 Million SEK | -14.05% |
| 2014 | 10.33 Million SEK | -10.13% |
| 2013 | 11.49 Million SEK | -34.08% |
| 2012 | 17.43 Million SEK | 0.38% |
| 2011 | 17.37 Million SEK | -12.59% |
| 2010 | 19.87 Million SEK | -3.84% |
| 2009 | 20.66 Million SEK | -3.59% |
| 2008 | 21.43 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 42.56 Million SEK | 0.0% |
| 2024 Q1 | 42.56 Million SEK | 1.45% |
| 2023 Q1 | 24.55 Million SEK | 4.73% |
| 2023 Q2 | 24.55 Million SEK | 0.0% |
| 2023 Q3 | 41.95 Million SEK | 70.91% |
| 2023 Q4 | 41.95 Million SEK | 0.0% |
| 2023 FY | 41.95 Million SEK | 78.99% |
| 2022 Q4 | 23.44 Million SEK | -14.42% |
| 2022 FY | 23.44 Million SEK | -1.35% |
| 2022 Q1 | 19.28 Million SEK | -18.87% |
| 2022 Q2 | 31.42 Million SEK | 62.97% |
| 2022 Q3 | 27.39 Million SEK | -12.82% |
| 2021 Q4 | 23.76 Million SEK | -4.27% |
| 2021 Q3 | 24.82 Million SEK | 20.14% |
| 2021 Q2 | 20.66 Million SEK | 3.67% |
| 2021 Q1 | 19.93 Million SEK | -2.97% |
| 2021 FY | 23.76 Million SEK | 15.68% |
| 2020 Q4 | 20.54 Million SEK | -27.86% |
| 2020 Q2 | 15.3 Million SEK | 18.26% |
| 2020 Q3 | 28.47 Million SEK | 86.03% |
| 2020 Q1 | 12.94 Million SEK | -14.89% |
| 2020 FY | 20.54 Million SEK | 35.07% |
| 2019 Q2 | 10.6 Million SEK | -29.85% |
| 2019 Q4 | 15.2 Million SEK | -25.22% |
| 2019 FY | 15.2 Million SEK | 63.05% |
| 2019 Q1 | 15.12 Million SEK | 62.11% |
| 2019 Q3 | 20.33 Million SEK | 91.74% |
| 2018 Q3 | 18.46 Million SEK | -7.33% |
| 2018 FY | 9.32 Million SEK | -26.7% |
| 2018 Q4 | 9.32 Million SEK | -49.48% |
| 2018 Q2 | 19.92 Million SEK | 73.25% |
| 2018 Q1 | 11.5 Million SEK | -9.62% |
| 2017 FY | 12.72 Million SEK | -42.4% |
| 2017 Q1 | 23.98 Million SEK | 8.58% |
| 2017 Q2 | 11.64 Million SEK | -51.46% |
| 2017 Q3 | 13.01 Million SEK | 11.75% |
| 2017 Q4 | 12.72 Million SEK | -2.2% |
| 2016 Q1 | - SEK | -100.0% |
| 2016 FY | 22.09 Million SEK | 148.76% |
| 2016 Q2 | 7.22 Million SEK | 0.0% |
| 2016 Q3 | - SEK | -100.0% |
| 2016 Q4 | 22.09 Million SEK | 0.0% |
| 2015 Q4 | 8.88 Million SEK | 0.0% |
| 2015 FY | 8.88 Million SEK | -14.05% |
| 2015 Q2 | 9.86 Million SEK | 0.0% |
| 2014 FY | 10.33 Million SEK | -10.13% |
| 2014 Q4 | 10.33 Million SEK | 0.0% |
| 2014 Q2 | 10.72 Million SEK | 0.0% |
| 2013 FY | 11.49 Million SEK | -34.08% |
| 2013 Q2 | 11.35 Million SEK | 0.0% |
| 2013 Q4 | 11.49 Million SEK | 0.0% |
| 2012 FY | 17.43 Million SEK | 0.38% |
| 2012 Q4 | 17.43 Million SEK | 0.0% |
| 2012 Q2 | 17 Million SEK | 0.0% |
| 2011 Q2 | 20.99 Million SEK | 0.0% |
| 2011 FY | 17.37 Million SEK | -12.59% |
| 2010 Q2 | 19.59 Million SEK | 0.0% |
| 2010 FY | 19.87 Million SEK | -3.84% |
| 2009 FY | 20.66 Million SEK | -3.59% |
| 2008 FY | 21.43 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Asarina Pharma AB (publ) | 6.07 Million SEK | -590.456% |
| BioArctic AB (publ) | 1.18 Billion SEK | 96.462% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -109.366% |
| CombiGene AB (publ) | 120.61 Million SEK | 65.212% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | 80.667% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | -39.061% |
| OncoZenge AB (publ) | 20.34 Million SEK | -106.288% |
| Alligator Bioscience AB (publ) | 118.45 Million SEK | 64.577% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 97.792% |
| Mendus AB (publ) | 755.95 Million SEK | 94.45% |
| LIDDS AB (publ) | 17.65 Million SEK | -137.661% |
| Lipum AB (publ) | 12.11 Million SEK | -246.482% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | 84.947% |
| Simris Alg AB (publ) | 174.55 Million SEK | 75.962% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | 20.81% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | -93.334% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 93.579% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 94.517% |
| Ziccum AB (publ) | 14.97 Million SEK | -180.25% |
| AcouSort AB (publ) | 34.51 Million SEK | -21.574% |
| Active Biotech AB (publ) | 44 Million SEK | 4.639% |
| Alzinova AB (publ) | 123.18 Million SEK | 65.939% |
| Amniotics AB (publ) | 26.08 Million SEK | -60.849% |
| Camurus AB (publ) | 1.9 Billion SEK | 97.801% |
| Cantargia AB (publ) | 223.71 Million SEK | 81.244% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -182.191% |
| Genovis AB (publ.) | 288.85 Million SEK | 85.474% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | 50.768% |
| Isofol Medical AB (publ) | 140.59 Million SEK | 70.157% |
| Intervacc AB (publ) | 259.61 Million SEK | 83.838% |
| Kancera AB (publ) | 65.64 Million SEK | 36.08% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 96.666% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | -24.871% |
| NextCell Pharma AB | 81.28 Million SEK | 48.382% |
| Saniona AB (publ) | 64.14 Million SEK | 34.585% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 91.545% |
| Xintela AB (publ) | 18.39 Million SEK | -128.1% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | 32.733% |
| Corline Biomedical AB | 100.1 Million SEK | 58.085% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | 76.311% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | 32.49% |
| Aptahem AB (publ) | 63.02 Million SEK | 33.425% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 88.057% |
| Fluicell AB (publ) | 9.34 Million SEK | -349.24% |
| Biovica International AB (publ) | 131.4 Million SEK | 68.07% |
| Abliva AB (publ) | 87.49 Million SEK | 52.046% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 94.481% |
| 2cureX AB (publ) | 16.62 Million SEK | -152.385% |
| I-Tech AB | 152.44 Million SEK | 72.476% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 95.878% |
| Cyxone AB (publ) | 43.65 Million SEK | 3.885% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | 46.679% |
| Biosergen AB | 7.2 Million SEK | -482.683% |
| Nanologica AB (publ) | 77.42 Million SEK | 45.81% |
| SynAct Pharma AB | 228.01 Million SEK | 81.598% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | -56.78% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 97.003% |
| Oncopeptides AB (publ) | 238.37 Million SEK | 82.398% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -396.263% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | 51.811% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | -47.183% |